Patent: 8,552,056
✉ Email this page to a colleague
Summary for Patent: 8,552,056
Title: | Biologically active taxane analogs and methods of treatment by oral administration |
Abstract: | The present invention relates to a novel chemical compound of formula S-(1): ##STR00001## for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents. |
Inventor(s): | McChesney; James D. (Etta, MS), Tapolsky; Gilles (Boulder, CO), Emerson; David E. (Longmont, CO), Marshall; John (Washington, DC), Ahmed; Tauseef (Hawthorne, NY), Cohn; Allen (Denver, CO), Kurman; Michael (Upper Saddle River, NJ), Modiano; Manuel (Tucson, AZ) |
Assignee: | Tapestry Pharmaceuticals, Inc. (Boulder, CO) |
Application Number: | 13/620,852 |
Patent Claims: | see list of patent claims |
Details for Patent 8,552,056
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2039-02-26 |
Servier Pharmaceuticals Llc | ONCASPAR | pegaspargase | Injection | 103411 | 02/01/1994 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2039-02-26 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2039-02-26 |
Eisai, Incorporated | ONTAK | denileukin diftitox | Injection | 103767 | 02/05/1999 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |